NBC News @NBCNews
The FDA failed to adhere to its own guidance and internal practices during the approval process for Biogen’s Alzheimer’s drug, which was “rife with irregularities,” a congressional report says. https://t.co/cl0UviPzlh — PolitiTweet.org
